<table class="infobox infobox-institution">
<tr>
<th class="infobox-header" colspan="2">Washington University in St. Louis</th>
</tr>
<tr>
<td class="infobox-image" colspan="2">
<em>Logo placeholder</em>
</td>
</tr>
<tr>
<td class="label">Location</td>
<td>St. Louis, MO, USA</td>
</tr>
<tr>
<td class="label">Type</td>
<td>University</td>
</tr>
<tr>
<td class="label">Website</td>
<td><a href="https://wustl.edu/" target="_blank">https://wustl.edu/</a></td>
</tr>
<tr>
<td class="label">Focus Areas</td>
<td>[Alzheimer's Disease](/diseases/alzheimers), [Parkinson's Disease](/diseases/parkinsons-disease), [Biomarkers](/mechanisms/biomarkers-ad)</td>
</tr>
<tr>
<td class="label">Departments</td>
<td>Department of Neurology</td>
</tr>
</table>
Washington University in St. Louis
Overview
Washington University School of Medicine in St. Louis is one of the nation's leading research institutions, consistently ranked among the top medical schools for research funding and excellence[@dian2024]. The university's Knight Initiative for Brain Resilience and Department of Neurology house comprehensive research programs in Alzheimer's disease, Parkinson's disease, and related neurodegenerative disorders.
...<table class="infobox infobox-institution">
<tr>
<th class="infobox-header" colspan="2">Washington University in St. Louis</th>
</tr>
<tr>
<td class="infobox-image" colspan="2">
<em>Logo placeholder</em>
</td>
</tr>
<tr>
<td class="label">Location</td>
<td>St. Louis, MO, USA</td>
</tr>
<tr>
<td class="label">Type</td>
<td>University</td>
</tr>
<tr>
<td class="label">Website</td>
<td><a href="https://wustl.edu/" target="_blank">https://wustl.edu/</a></td>
</tr>
<tr>
<td class="label">Focus Areas</td>
<td>[Alzheimer's Disease](/diseases/alzheimers), [Parkinson's Disease](/diseases/parkinsons-disease), [Biomarkers](/mechanisms/biomarkers-ad)</td>
</tr>
<tr>
<td class="label">Departments</td>
<td>Department of Neurology</td>
</tr>
</table>
Washington University in St. Louis
Overview
Washington University School of Medicine in St. Louis is one of the nation's leading research institutions, consistently ranked among the top medical schools for research funding and excellence[@dian2024]. The university's Knight Initiative for Brain Resilience and Department of Neurology house comprehensive research programs in Alzheimer's disease, Parkinson's disease, and related neurodegenerative disorders.
Washington University's Knight Alzheimer Prevention Initiative and Healthy Aging and Senescence (HAS) Program represent pioneering efforts to understand and prevent age-related neurodegenerative diseases[@dian2024a]. The institution's strong basic science foundation enables translation of fundamental discoveries into clinical applications.
Research Programs
Knight Initiative for Brain Resilience
The Knight Initiative represents a major initiative to understand brain resilience:
- Resilience Biomarkers: Identification of biological factors that protect against cognitive decline despite age-related pathology[@knight2024].
- Senescence Research: Investigation of cellular senescence and its contribution to neurodegeneration.
- Intervention Testing: Preclinical and clinical studies of senolytic and other anti-aging compounds.
Alzheimer's Disease Research
Washington University leads multiple major research initiatives:
- Dominantly Inherited Alzheimer Network (DIAN): International consortium studying autosomal dominant Alzheimer's disease[^4].
- Anti-amyloid Trials: Leadership in clinical trials of monoclonal antibodies targeting amyloid-beta.
- Biomarker Development: Pioneering work on CSF and blood biomarkers including tau species.
Parkinson's Disease Research
The movement disorders program investigates:
- Alpha-synuclein Biology: Basic science studies on protein aggregation and spread.
- Clinical Trials: Novel therapeutic candidates for disease modification.
- Deep Brain Stimulation: Advanced surgical and programming approaches.
Neuroimaging Research
The Mallinckrodt Institute of Radiology maintains cutting-edge programs:
- Amyloid and Tau PET: First-in-human studies of novel imaging agents.
- MRI Methods: Advanced techniques for measuring brain structure and connectivity.
- Multi-modal Integration: Combining neuroimaging with biomarker and clinical data.
Key Research Facilities
- Knight Building: Dedicated research space for neurodegeneration studies.
- Knight Biobank: Repository of biospecimens from well-characterized patients.
- Charles F. Knight Center: Clinical research facility for human subjects studies.
Clinical Trials
| Condition | Focus | Phase | Status |
|-----------|-------|-------|--------|
| Alzheimer's disease | DIAN intervention | Phase 2/3 | Active |
| Alzheimer's disease | Anti-amyloid | Phase 3 | Various |
| Parkinson's disease | Synuclein inhibitor | Phase 2 | Recruiting |
| FTD | Tau antibody | Phase 2 | Enrolling |
Key Researchers
| Researcher | H-index | Focus Areas |
|------------|---------|-------------|
| [John C. M. Morris](/researchers/john-c-morris) | 130 | Alzheimer's disease, biomarkers |
| [David M. Holtzman](/david-m.-holtzman) | 115 | Alzheimer's disease, amyloid |
| Randall J. Bateman | 90 | Clinical trials, biomarkers |
| Suzanne R. L. Steh | 80 | Parkinson's disease, movement disorders |
Contributions to the Field
DIAN Network: Establishment and leadership of international autosomal dominant AD consortium.
Amyloid hypothesis: Seminal contributions to understanding amyloid-beta biology.
Biomarker standardization: Leadership in CSF biomarker standardization efforts.
Resilience research: Pioneering work on brain resilience and cognitive reserve.External Links
- Official Website: [https://wustl.edu/](https://wustl.edu/)
- School of Medicine: [https://medicine.wustl.edu/](https://medicine.wustl.edu/)
- Knight Initiative: [https://knightadrc.wustl.edu/](https://knightadrc.wustl.edu/)
Technology and Innovation
Washington University's research benefits from cutting-edge technologies:
- Cryo-EM: Advanced cryo-electron microscopy for protein structure determination.
- Single-cell Genomics: Single-cell RNA sequencing to characterize cellular heterogeneity.
- High-throughput Screening: Automated drug screening platforms for therapeutic discovery.
Education and Training
WUSTL provides exceptional training in neurodegenerative research:
- Neurology Residency: Comprehensive training program with cognitive and movement disorder tracks.
- Postdoctoral Programs: Extensive opportunities for research training in neurodegeneration.
- Graduate Education: PhD programs through the Division of Biology and Biomedical Sciences.
Collaborations
WUSTL maintains key partnerships:
- DIAN Registry: International network for autosomal dominant Alzheimer's disease.
- Knight ADRC: National Alzheimer's Disease Research Center network.
- Industry Partnerships: Collaborations with pharmaceutical companies on therapeutic development.
Future Directions
Washington University research priorities:
Resilience Studies: Understanding factors that protect against cognitive decline.
Combination Therapies: Testing multi-target treatment approaches.
Early Intervention: Initiating treatment in preclinical stages.
Biomarker Development: Blood-based tests for early detection.Dominantly Inherited Alzheimer Network (DIAN)
Washington University leads the international Dominantly Inherited Alzheimer Network (DIAN), a groundbreaking observational and therapeutic trial studying individuals with genetic mutations causing autosomal dominant Alzheimer's disease[@dian2024]. DIAN has enrolled over 500 participants from families worldwide with known APP, PSEN1, or PSEN2 mutations, enabling studies of preclinical disease progression and biomarker changes decades before symptom onset.
The DIAN Therapeutic Trials Unit (DTTU) conducts pioneering prevention trials in mutation carriers, testing anti-amyloid and anti-tau therapies before significant cognitive impairment develops. This preventive approach represents a paradigm shift in Alzheimer's disease clinical research[@dian2024a].
Knight Initiative for Brain Resilience
The Knight Initiative for Brain Resilience focuses on understanding why some individuals maintain cognitive function despite evidence of neurodegenerative pathology. This research addresses:
- Cognitive Reserve: How education, occupational complexity, and lifestyle factors influence brain resilience
- Neuroimmune Interactions: The role of microglia and neuroinflammation in disease progression
- Metabolic Factors: How diabetes, obesity, and cardiovascular health affect brain aging
Clinical Training Programs
Washington University trains the next generation of neurodegeneration researchers through:
- Neurology Residency: Comprehensive training in movement disorders and cognitive neurology
- Postdoctoral Fellowships: Basic and clinical research training in neurodegeneration
- Clinical Trials Training: Specialized curriculum in clinical trial design and execution
The annual Knight Alzheimer's Research Conference brings together international experts to discuss latest advances in the field[@knight2024].
References
[Morris JC, et al. Tau and amyloid PET in cognitively normal aging. JAMA Neurol (2019)](https://pubmed.ncbi.nlm.nih.gov/31268499/)
[Holtzman DM, et al. Apolipoprotein E in Alzheimer's disease. Nat Rev Neurol (2018)](https://pubmed.ncbi.nlm.nih.gov/29512652/)
[Bateman RJ, et al. Autosomal-dominant Alzheimer's disease trials. Nat Rev Neurol (2017)](https://pubmed.ncbi.nlm.nih.gov/28261412/)
[DIAN International Research Network](https://dian.wustl.edu/)
[DIAN Therapeutic Trials Unit](https://dian.wustl.edu/clinical-trials/)
[Knight Alzheimer's Research Conference](https://knightadrc.wustl.edu/)